Determination of Three Tyrosine Kinase Inhibitors and One Active Metabolite by an Identical and Validated Ultra-performance Liquid Chromatography-DAD Method in Human Plasma
Tyrosine kinase inhibitors (TKIs) are a class of targeted drugs with antiangiogenic and antitumor activities.
Due to inter-individual metabolic variability, an accurate therapeutic drug monitoring (TDM) represents a key element for
the patient treatment. Here a fast and easily accessible method for the quantification of 3 TKIs (with one active metabolite)
in human plasma after extraction is described.
Sample pre-treatments were performed by solid phase extraction (Oasis® MCX μElution technology). Chromatographic
separation was performed on a Waters Acquity UPLC® system with diode array detection (DAD) using a gradient of ammonium
formate-acetonitrile on BEH C18 2.1x50 mm column.
The analytical methods were validated by using the accuracy profiles approach (β-expectation set at 95%). The methods
were successfully validated for sunitinib (10 – 250 ng/mL), N-desethyl sunitinib (15 – 250 ng/mL), axitinib (15 – 250
ng/mL) and pazopanib (20 – 200 μg/mL). The first concentration levels validated were considered as limit of quantification
The validated method will be used in a clinical research study to determine TKI plasma levels and in this way help physicians
to optimize the posology in order to achieve the best therapeutic response for their patients.
Keywords: Accuracy profiles, μSPE, tyrosine kinase inhibitors, UPLC, UV-VIS detection, validation.
Rights & PermissionsPrintExport